Open AccessPlasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
Author(s) -
Vincenza Conteduca,
Daniel Wetterskog,
Emanuela Scarpi,
Alessandro Romanel,
Giorgia Gurioli,
Anuradha Jayaram,
Cristian Lolli,
Delila Gasi Tandefelt,
Giuseppe Schepisi,
Chiara Casadei,
Anna Wingate,
Federica Matteucci,
Giovanni Paganelli,
Enrique González-Billalabeitia,
Francesca Demichelis,
Ugo De Giorgi,
Gerhardt Attard
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0969-5
Subject(s) - prostate cancer , interquartile range , odds ratio , medicine , oncology , confidence interval , androgen deprivation therapy , cancer
Plasma tumour DNA (ptDNA) levels on treatment are associated with response in a variety of cancers. However, the role of ptDNA in prostate cancer monitoring remains largely unexplored. Here we characterised on-treatment ptDNA dynamics and evaluated its potential for early assessment of therapy efficacy for metastatic castration-resistant prostate cancer (mCRPC).